2019•Clinical Lymphoma Myeloma & LeukemiaRequires access

Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience

Tahir Darçın, Tuğçe Nur Yiğenoğlu, Derya Şahin, Mehmet Bakırtaş, Semih Başçı, Alparslan Merdin, Jale Yıldız, Bahar Uncu Ulu, Ayşegül Tetik, Dicle İskender, Merih Kızıl Çakar, Mehmet Sinan Dal, Fevzi Altuntaş

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Bendamustine, Medicine, Refractory (planetary science), Rituximab, Internal medicine, Lymphoma, Oncology, Biology